相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL).
R. W. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
Linkers Having a Crucial Role in Antibody-Drug Conjugates
Jun Lu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Current Status: Site-Specific Antibody Drug Conjugates
Dominik Schumacher et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2016)
Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates
Patrick J. Burke et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Recent advances in the construction of antibody-drug conjugates (vol 8, pg 114, 2016)
Vijay Chudasama et al.
NATURE CHEMISTRY (2016)
Expanding the Reach of Antibody-Drug Conjugates
Ravi V. J. Chari
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule
Jianhong Yang et al.
NATURE COMMUNICATIONS (2016)
Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules
Yuxi Wang et al.
MOLECULAR PHARMACOLOGY (2016)
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
Jessica R. McCombs et al.
AAPS JOURNAL (2015)
Versatile and Efficient Site-Specific Protein Functionalization by Tubulin Tyrosine Ligase
Dominik Schumacher et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases
Pradman K. Qasba
BIOCONJUGATE CHEMISTRY (2015)
Site-Specific Antibody-Drug Conjugates: The Nexus of Biciorthogonal Chemistry, Protein Engineering, and Drug Development
Paresh Agarwal et al.
BIOCONJUGATE CHEMISTRY (2015)
The cryptophycins as potent payloads for antibody drug conjugates
Vishal A. Verma et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Antibody-drug conjugates as novel anti-cancer chemotherapeutics
Christina Peters et al.
BIOSCIENCE REPORTS (2015)
In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios
Penny Bryant et al.
MOLECULAR PHARMACEUTICS (2015)
Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability
Satish K. Singh et al.
PHARMACEUTICAL RESEARCH (2015)
Current ADC Linker Chemistry
Nareshkumar Jain et al.
PHARMACEUTICAL RESEARCH (2015)
A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
Antoine Maruani et al.
NATURE COMMUNICATIONS (2015)
Structural Basis of Microtubule Stabilization by Laulimalide and Peloruside A
Andrea E. Prota et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy
Ravi V. J. Chari et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
George Badescu et al.
BIOCONJUGATE CHEMISTRY (2014)
Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes
Penelope M. Drake et al.
BIOCONJUGATE CHEMISTRY (2014)
Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling
Ruth Cohen et al.
CANCER RESEARCH (2014)
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Laleh Amiri-Kordestani et al.
CLINICAL CANCER RESEARCH (2014)
Antibody-drug conjugates: current status and future directions
Heidi L. Perez et al.
DRUG DISCOVERY TODAY (2014)
Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates
Aaron E. Albers et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
The tubulin code: Molecular components, readout mechanisms, and functions
Carsten Janke
JOURNAL OF CELL BIOLOGY (2014)
Synthetic Reactions with Rare Taccalonolides Reveal the Value of C-22,23 Epoxidation for Microtubule Stabilizing Potency
Jiangnan Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: design, synthesis and biological evaluation
Giordano Lesma et al.
MOLECULAR DIVERSITY (2014)
Site-specific antibody drug conjugates for cancer therapy
Siler Panowski et al.
MABS (2014)
The Next Generation of Antibody Drug Conjugates
Fiona Mack et al.
SEMINARS IN ONCOLOGY (2014)
Enzyme-Mediated Methodology for the Site-Specific Radiolabeling of Antibodies Based on Catalyst-Free Click Chemistry
Brian M. Zeglis et al.
BIOCONJUGATE CHEMISTRY (2013)
Taccalonolide Binding to Tubulin Imparts Microtubule Stability and Potent In Vivo Activity
A. L. Risinger et al.
CANCER RESEARCH (2013)
Colchicine Semisynthetics: Chemotherapeutics for Cancer?
G. Sivakumar
CURRENT MEDICINAL CHEMISTRY (2013)
Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Harish Rajak et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Structural basis of tubulin tyrosination by tubulin tyrosine ligase
Andrea E. Prota et al.
JOURNAL OF CELL BIOLOGY (2013)
Conjugates of Modified Cryptophycins and RGD-Peptides Enter Target Cells by Endocytosis
Markus Nahrwold et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
Michael Ritchie et al.
MABS (2013)
Recent approaches for the synthesis of modified cryptophycins
Christine Weiss et al.
NATURAL PRODUCT REPORTS (2013)
Synthesis and structure-activity relationship studies of novel tubulysin U analogues - effect on cytotoxicity of structural variations in the tubuvaline fragment
Sreejith P. Shankar et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2013)
Total synthesis and biological evaluation of fluorinated cryptophycins
Christine Weiss et al.
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY (2012)
Novel Drugs Targeting Microtubules: the Role of Epothilones
Gabriella Ferrandina et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Polymeric Dibromomaleimides As Extremely Efficient Disulfide Bridging Bioconjugation and Pegylation Agents
Mathew W. Jones et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
Hans K. Erickson et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D. Senter et al.
NATURE BIOTECHNOLOGY (2012)
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Jun Y. Axup et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Design of Antibody-Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism
Xiuxia Sun et al.
BIOCONJUGATE CHEMISTRY (2011)
Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
Stephen I. Rudnick et al.
CANCER RESEARCH (2011)
Developments of Combretastatin A-4 Derivatives as Anticancer Agents
Y. Shan et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates
Robert Y. Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Potent Taccalonolides, AF and AJ, Inform Significant Structure-Activity Relationships and Tubulin as the Binding Site of These Microtubule Stabilizers
Jing Li et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
Franco Dosio et al.
TOXINS (2011)
Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
Simone Jeger et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody-Maytansinoid Conjugates
Hans K. Erickson et al.
BIOCONJUGATE CHEMISTRY (2010)
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Yelena V. Kovtun et al.
CANCER RESEARCH (2010)
Overview of the immune response
David D. Chaplin
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted Chemotherapy
Sherly Quiles et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Approaches for the Synthesis of Functionalized Cryptophycins
Benedikt Sammet et al.
JOURNAL OF ORGANIC CHEMISTRY (2010)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clicktophycin-52: A Bioactive Cryptophycin-52 Triazole Analogue
Markus Nahrwold et al.
ORGANIC LETTERS (2010)
Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
Andrew G. Polson et al.
CANCER RESEARCH (2009)
Polymeric Tubulysin-Peptide Nanoparticles with Potent Antitumor Activity
Thomas Schluep et al.
CLINICAL CANCER RESEARCH (2009)
Recent advances of novel targeted therapy in non-small cell lung cancer
Jed A. Katzel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Michael M. Schmidt et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeted cancer therapy: Conferring specificity to cytotoxic drugs
Ravi V. J. Chari
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Greg M. Thurber et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
Clinical status of anti-cancer agents derived from marine sources
Ram Singh et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2008)
Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate
Svetlana O. Doronina et al.
BIOCONJUGATE CHEMISTRY (2008)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Tamoxifen: Catalyst for the change to targeted therapy
V. Craig Jordan
EUROPEAN JOURNAL OF CANCER (2008)
Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)
Toshirou Nishida et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2008)
Monoclonal antibodies in cancer therapy: 25 years of progress
Robert K. Oldham et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Tracking the ends: a dynamic protein network controls the fate of microtubule tips
Anna Akhmanova et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Design, synthesis, and biological properties of highly potent tubulysin D analogues
Andrew W. Patterson et al.
CHEMISTRY-A EUROPEAN JOURNAL (2007)
Semisynthetic maytansine analogues for the targeted treatment of cancer
Wayne C. Widdison et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Development and properties of β-glucuronide linkers for monoclonal antibody-drug conjugates
SC Jeffrey et al.
BIOCONJUGATE CHEMISTRY (2006)
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
HK Erickson et al.
CANCER RESEARCH (2006)
Structural mechanisms underlying nucleotide-dependent self-assembly of tubulin and its relatives
E Nogales et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2006)
Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria
MW Khalil et al.
CHEMBIOCHEM (2006)
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer
G D'Agostino et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
SO Doronina et al.
BIOCONJUGATE CHEMISTRY (2006)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
RA Larson et al.
CANCER (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Sortase-mediated protein ligation: A new method for protein engineering
HY Mao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
Human antibody - Fc receptor interactions illuminated by crystal structures
JM Woof et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Total synthesis and anti-tubulin activity of Epi-C3 analogues of cryptophycin-24
SB Buck et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Recent developments in the maytansinoid antitumor agents
JM Cassady et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2004)
Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules
G Krishnamurthy et al.
BIOCHEMISTRY (2003)
Design, synthesis, and evaluation of azepine-based cryptophycin mimetics
AB Smith et al.
TETRAHEDRON (2003)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
A convergent approach to cryptophycin 52 analogues: Synthesis and biological evaluation of a novel series of fragment A epoxides and chlorohydrins
RS Al-Awar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer
MJ Edelman et al.
LUNG CANCER (2003)
Tumor-specific novel taxoid-monoclonal antibody conjugates
I Ojima et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule
C Sessa et al.
EUROPEAN JOURNAL OF CANCER (2002)
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
GM Dubowchik et al.
BIOCONJUGATE CHEMISTRY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-Doxorubicin in patients with Lewis Y-expressing epithelial tumors
MN Saleh et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer
LM Krug et al.
ANNALS OF ONCOLOGY (2000)
Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli - Production, isolation, physico-chemical and biological properties
F Sasse et al.
JOURNAL OF ANTIBIOTICS (2000)
分享论文
